News | March 10, 2014

ImaCor’s hTEE Recognized for Hemodynamic Management Solution in Critical Care

ImaCor ClariTEE Zura EVO hTEE Ultrasound transesophageal TEE Cardiac

March 10, 2014 — ImaCor Inc., the developer of hemodynamic transesophageal echocardiography (hTEE) technology, announced four academic hTEE presentations. Physicians are publicly recognizing hTEE as a tool for managing complex ICU patients. Nick Fletcher, MBBS presented hTEE during the Heart Failure: State of the Art and Future Perspectives 5-day European Association of Cardio-Thoracic Surgery (EACTS) advanced module in Windsor, UK; Serban Bubenek, M.D., Ph.D described hTEE as the Advanced Hemodynamic Management solution at the Autumn Meeting of the European Society of Anesthesiology (ESA) in Timisoara, Romania; and Margarita Camacho, M.D. and Claudia Gidea, M.D. share hTEE case findings at the Tufts 6th Annual New England Heart Failure and Transplantation Network Conference in Waltham, Mass.

This follows an Oct. 8, 2013 session on hTEE Advanced Hemodynamic Management that was part of the scientific program at the 27th Annual Meeting of EACTS in Vienna, Austria. Speakers included A. Pieter Kappetein, M.D., Ph.D, Matthias Loebe M.D., Ph.D, and Simon Maltais M.D., Ph.D. During the 90-minute session, three videos of live hTEE case demonstrations were also presented from Vanderbilt University Medical Center, Nashville, Barnes-Jewish Hospital, St. Louis and Thomas Jefferson University Medical Center, Philadelphia.

hTEE is enabled through a miniature, disposable probe that can be placed in a patient for up to 72 hours to directly observe cardiac filling and function over time. It is easy-to-use and purpose-built for the ICU staff. With the growing population of older, sicker patients with multiple comorbidities, physicians recognize the benefits of hTEE’s continuous hemodynamic management to guide therapy. 

For more information: www.imacorinc.com

Related Content

ASE Releases Guidelines for Transesophageal Echo in Congenital Heart Disease
News | Ultrasound Transesophageal echo (TEE) | February 05, 2019
February 5, 2019 – The American Society of Echocardiography (ASE) released a new document that provides a comprehensi
Figure 1: Segmentation performed on the left atrium, left ventricle and mitral bioprosthesis. Landmarks are placed on the site of optimal transseptal access into the left atrium and the mitral PVL.

Figure 1: Segmentation performed on the left atrium, left ventricle and mitral bioprosthesis. Landmarks are placed on the site of optimal transseptal access into the left atrium and the mitral PVL.

Sponsored Content | Case Study | Ultrasound Transesophageal echo (TEE) | September 05, 2018 | Cyril Danielkutty B.E., Dillon Weiss, B.S., Chad A Kliger, M.D., M.S.
Transcatheter interventions have become a mainstay in cardiac care as treatments for structural and congenital heart
FDA Clears Visura Technologies' TEE Camera Assist Device System
Technology | Ultrasound Transesophageal echo (TEE) | July 10, 2018
July 10, 2018 — Evanston, Ill.-based startup Visura Technologies has received 510(k) clearance from the U.S.
Stroke2prevent Receives FDA 510(k) Clearance for A-View
Technology | Ultrasound Transesophageal echo (TEE) | June 20, 2017
June 20, 2017 — Dutch medical device company Stroke2prevent BV recently announced it has received U.S.
News | Ultrasound Transesophageal echo (TEE) | April 21, 2016
CS Medical announced the release of their newest product designed to aid in the circle of care for transesophageal echo...
Overlay Init